摘要
甲状旁腺功能减退症是甲状旁腺素分泌过少和(或)效应不足所致的一组以血清钙浓度降低为主的临床综合征。目前,临床上主要采用补充钙剂或维生素D类似物等方法进行对症治疗。虽然能缓解症状,但需终身服药、价格不菲。近年来,随着精准医疗概念提出,个体化或基因靶向药物治疗已成为科学研究的热点,也使甲状旁腺功能减退症的靶向干预治疗成为可能。因此,针对甲状旁腺功能减退症的分子标志物、基因和靶向药物治疗的相关研究进行综合荟萃分析,可为临床合理治疗提供科学依据和理论指导,具有重要参考价值和指导意义。
Hypoparathyroidism is a clinical syndrome characterized by decline of serum calcium concentration due to insufficient parathormone secretion or insufficient efficacy. Symptomatic treatments such as supplement with calcium or vitamin D analogue are mainly adopted in clinical currently. Though the symptoms can be alleviated, the patients have to take expensive medicine lifelong. With the proposing of the accurate medical concept, individualized and gene targeted therapy has become a research hotspot, which makes it possible of the targeted intervention for hypoparathyroidism. Therefore, this study systemically reviewed the related research about the screening of molecular markers, gene and targeted drug treatment for hypoparathyroidism, to provide the scientific basis and theoretical guidance for clinical reasonable treatment.
出处
《中华临床医师杂志(电子版)》
CAS
2016年第22期3417-3420,共4页
Chinese Journal of Clinicians(Electronic Edition)
基金
国家自然科学基金(81070637
81570742)
山东省科技发展计划项目(科技公关项目)(2010GSF10228
2012GGH11862
2014GSF118118)
山东省自然基金(Y2008C73
ZR2010HM044
ZR2016HQ26)
济南市科技发展计划(201602172)